Promoted Content Promoted Content

X

Find Drugs for Otolaryngology (Ear, Nose, Throat) in Phase II Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mometasone Furoate

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: LYR-210

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: LianBio

            Deal Size: $147.0 million Upfront Cash: $12.0 million

            Deal Type: Partnership June 02, 2021

            Details:

            LYR-210 is an anti-inflammatory, intra-nasal drug matrix in late-stage development that is designed to treat chronic rhinosinusitis (CRS), a debilitating inflammatory disease of the nasal passages.